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Introduction 
Although disruption in several neurochemical systems has been 
described in Alzheimer's disease (AD), the most robust evidence 
relates the core cognitive impairment to significant deficits in 
brain acetyleholine function (Coyle et al 1983). The eholinergic 
hypothesis of AD has led to treatment strategies aimed at en- 
hancing central cholinergic neurotransmission (Bartus et al 1982). 
There is modest improvement in cognition after treatment with 
centrally active acetylcholinesterase inhibitors, such as physo- 
stigmine (Davis and Mohs 1982; Thai et al 1989). Enhancing 
the efficacy of cholinergic agents would provide a novel thera- 
peutic approach based on the eholinergic hypothesis. One pos- 
sibility is coadministration of a cholinomimetic drug with a neu- 
romodulatory agent known to augment cholinergic activity. The 
important role for neuropeptides in the modulation of brain neu- 
rotransmitter function is well established (Hokfelt et al 1989); 
thus, a "procholinergic" modulatory neuropeptide might serve 
as a basis for such an approach. 
In addition to its role in the regulation of thyroid function, 
thyrotropin-releasing hormone (TRH) has long been recognized 
as a modulatory neuropeptide in the central nervous system (Hor- 
ita et al 1986). The procholinergic effects of TRH have been 
demonstrated in animal studies at several levels of organization 
in the central nervous system (Yarbrough 1983). We have pre- 
viously shown (Mellow et al 1989) that TRH can be given safely 
in high doses (required for central nervous system effects) to AD 
patients and produces behavioral activation and a small improve- 
ment in semantic memory. We have also shown it to reverse 
scopolamine-induced cognitive impairment in normal volunteers 
(Molehan et al 1990). We are currently testing the safety and 
feasibility of a peptide enhancement strategy, examining the cog- 
nitive and neuroendocrine effects of high-dose TRH in combi- 
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nation with physostigmine in AD patients. We herein report our 
initial experience in the first six subjects, in which we have tested 
the safety of this combination, as well as the hypothesis that 
TRH might modulate the effects of physostigmine. 
Methods 
Six patients (four men and two women; mean age, 69 -+ 7 years), 
taking no psychotropic medications and in good general health, 
who met NINCDS-ADRDA criteria for probable Alzbeimer's 
disease (McKhann et al 1984) underwent two separate study days 
(separated by at least 48 hours) while they were inpatients at the 
University of Michigan Hospital Clinical Research Center. Pa- 
tients all received pretreatment with glycopyrrolate (0. I-0.2 rag), 
a peripheral eholinergic antagonist. Patients (blinded to drug 
treatment conditions) then received (on randomized days) a 10- 
rain intravenous infusion of TRH (0. I or 0.3 mg/kg) or placebo, 
followed by a 30-rain infusion of physostigmine (0.5 or 1.0 rag). 
Patients had continuous electrocardiogram and vital sign moni- 
toring during and at least I hour after the drug infusions. Cog- 
nitive testing was performed each study day, prior to drug in- 
fusions and during the last 10-15 minutes of the physostigmine 
infusions, by a technician blinded to drug treatment condition. 
The psychometric battery included the Buschke Selective Re- 
minding Task, a letter retrieval task (a measure of verbal fluency), 
a picture memory test (a measure of automatic learning), and a 
digit span task. Patients were also asked to perform self-ratings 
( I -5  scale) on measures of arousal and mood. Serial blood sam- 
ples for neuroendocrine measures of central cholinergic activity 
were obtained prior to, during, and after drug infusions. Samples 
were collected in chilled ethylene glycol tetraacetic acid (EGTA)- 
treated tubes, centrifuged at 4°C, and plasma was stored at - 80°C 
until processing. Epinephrine was measured by modification of 
the method of Bouloux et al (1985), using high-pressure liquid 
chromatography with electrochemical detection. [3-Endorphin was 
measured by immunoradiometric assay (Voellmy et al 1988) (kits 
purchased from Nickels Institute, San Juan Capistrano, CA). 
Results of the cognitive and behavioral testing, as well as 
peak hormonal response and maximum vital sign changes, were 
all expressed as change scores (postinfusion minus preinfusion) 
for each day and analyzed by paired t-test, comparing the phy- 
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sostigmine day with the physostigmine plus TRH day for each 
patient. Three patients received physostigmine, 0.5 mg, plus 
TRH, 011 mg/kg, (or placebo) and three patients received phy- 
sostigmine, 1.0 rag, plus TRH, 0.3 mg/kg, (or placebo). Due to 
the small number of subjects, combined data were analyzed from 
all six subjects, in this preliminary study, corrections for multiple 
t-tests were not used. 
Results 
All patients tolerated the infusions without adverse effects on 
their vital signs or electrocardiogram. The only side effects ex- 
perienced were some nausea (in two patients) and transient shiv- 
ering (in three patients, those receiving the higher TRH dose). 
Patients' self.ratings of mood and arousal did not change between 
the physostigmine day and physostigmine plus TRH day. Systolic 
blood pressure increases were significantly greater on the phy- 
sostigminc plus TRH day. compared with the physostigmine day 
(26.8 ± 4.9 mm Hg versus 14.3 ± 3.0 mm Hg). There were 
no significant changes in any other vital signs. Patients performed 
significantly better on measures of verbal fluency on the phy- 
sostigmine plus TRH day than on the physostigmine day. In 
addition, patients had significantly fewer verbal intrusion errors 
on the physostigmine plus TRH day. On measures of delayed 
recall (word list learning), immediate recall (digit span), and 
automatic learning, there was no significant difference in per- 
formance between days. Although TRH improved performance 
on two cognitive measures, the overall response to physostzgmine 
in this patient sample was nonsignificant (data not shown). Peak 
plasma epinephrine response dunttg and after physoatigmine in- 
fusion was significantly increased on the physostigmine plus TRH 
days. The 13-endorphin response showed no significant difference 
between days and was quite variable in this sample', only three 
of six patients showed any rise in ~-endorphin after drug infu- 
sions. The results are summarized in Table 1, 
Discussion 
This pilot study represents the first attempt at a peptide enhance- 
ment strategy in AD, using the procholinergic neuropeptide TRH 
in combination with the cholinesterase inhibitor physostigmine, 
We have found this combination to be safe and well tolerated in 
AD patients. The increases in blood pressure seen after both 
physostigmine and the combination of TRH plus physostigmine 
are consistent with both our own previous work (Mellow et al 
1989) and that of others (Janowsky et al 1985). Although we 
did not include a day in this study when TRH was administered 
alone, the magnitude of the blood pressure change on the phy- 
sostigmine plus TRH day suggests that the pressor effects of the 
two drugs are not synergistic, thereby reinforcing the safety of 
this strategy. On two n~easures of cognitive function, TRH im- 
proved performance when coadministered with physostigmine. 
These results are encouraging, because TRH appeared to have 
some enhancing effect even when the overall response to phy- 
sostigmine was nonsignificant (which suggests nonoptimal phy- 
sostigmine dosing in this patient sample). Because of the apparent 
biphasic dose-response curve for the effects of physostigmine 
(Davis and Mobs 1982; Mohs and Davis 1982), a rigorous test 
of any cholinergic enhancement strategy will require adequate 
dose-finding for each subject, to determine a best dose of phy- 
sostigmine to be eoadministered with high-dose TRH. Under 
these conditions, coadministration of TRH with physostigmine 
might yield more robust findings. Another limitation of the cur- 
rent study is the lack of test days in which patients received either 
placebo alone or TRH alone. Such a design would allow a more 
precise dissection of potential enhancing effects of TRH. Lacking 
this, however, the cognitive effects in patients receiving phy- 
sostigmine plus TRH still suggest an enhancement, because the 
pattern of improvement (decrease in intrusion errors) differs from 
that seen with TRH alone in our previous work (Mellow et al 
1989). 
It has been suggested that the plasma epinephrine response 
to physostigmine is mediated via a central cholinergic mechanism 
(Kennedy et al 1984), This response, as well as the I~-endorphin 
response has been shown to be blunted in AD (Raskind et al 
1989); the increase in peak epinephrine after high-dose TRH 
coadmiaistration might reflect a central marker of cholinergic 
enhancement, which could be correlated in future studies with 
results of behavioral and cognitive measurements. The lack of a 
test day with TRH alone makes these results somewhat complex 
to interpret. Although peripherally administered TRH does not 
Table I. Acute Effects of TRH-Physostigmine Infusions in Six Alzheimer's Disease (AD) 
Patients" 
Variable Physostigmine Physostigmine + TRH p 
Verbal fluency (words) -0.7 ± 0.4 0.9 ± 0.8 <0.04 
Intrusions (words) 3.3 ± 1.5 -9.2 ± 3.5 <0.04 
Recall (words) 1.9 ± 3.0 -2.8 ± 3.8 NS 
Digit span (digits) -0.4 --. 0.4 -0.3 ± 0.5 NS 
Peak A systolic BP (ram Hg) 14.3 ± 3.0 26.8 -+ 4.9 <0.04 
Peak A diastolic BP (ram Hg) 15.8 ± 2,4 t7.8 ± 2.6 NS 
Peak A pulse rate (bpm) 10.7 +_ 3.8 17.2 ± 6.3 NS 
Peak A epinephrine (pg/ml) 23.9 ± 15.7 64.7 ± 25.6 <0.03 
Peak A I~-endorphin (pg/ml) 30.2 ± 16.5 23.5 ± 26.2 NS 
~All variables are expressed as change scores (pestdrug minus predrug) __. SEM, and compared by paired I-test between 
days when patients received physostigmine alone and when they received physostigmine plus TRH, See text for details of drug 
administration and testing, "rRH, thyrotropin-releasing hormone: NS, not significant. 
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reliably produce plasma epinephrine increases (Morley et al 198 i ; 
Zaloga et al 1984), there is evidence that centrally administered 
TRH and its analogs increases epinephrine levels (Kabayama et 
al 1985; lshikawa et al 1990), Once again, a rigorous test of the 
utility of epinephrine response as a marker of TRH enhancement 
awaits a larger study in which the hormonal effects of TRH alone 
are studied in this paradigm. Tlne lack of a significant ~-endorphin 
response (which also may be cholinergically mediated) may be 
because the physostigmine dosing in this pilot study was not 
optimized. 
Further studies are under way to characterize snore fully the 
dose requirements for this enhancement paradigm in AD. Future 
research might extend the time frame of treatment to ions-term, 
combined drug administration, and the use of longer-acting an- 
alogs of both acetylcholinesterase inhibitors and TRH. The recent 
interest in the use of the oral cholinesterase inhibitor tacrine in 
AD (Fariow et al 1992; Davis et al 1992) rende~ this paradigm 
more timely in its clinical implications. Such work could lead 
to a novel treatment approach in the experimental pharmacology 
of AD. 
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